You are on Trendlyne United States. Click here to go to India website or make United States as your default

Finch Therapeutics Group Inc XNAS: FNCH

Finch Therapeutics Group Inc Live Share Price Today, Share Analysis and Chart

14.00 -0.10 (-0.71%)

1650.00% Gain from 52W Low

5,308 XNAS Volume

High volume today

XNAS 26 Mar, 2025 5:30 PM (EDT)

Board Meeting
The next board meeting for Finch Therapeutics Group Inc is on 01 Apr 2025 for the purpose of Finch Therapeutics Group Inc Annual Report for 2024 See details

Finch Therapeutics Group Inc Key Metrics

Select
All financials are in USD Million and price data in USD
VIEW MORE
Not Eligible
-
Expensive Valuation
10.3 / 100
Technically Neutral
56.2 / 100

Finch Therapeutics Group Inc Live Price Chart

Switch to TradingView
Fetching data ...

Finch Therapeutics Group Inc Stock Analysis

Finch Therapeutics Group Inc stock analysis with key metrics, changes, and trends.

Finch Therapeutics Group Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$0.11 M57.71%negative

Annual Revenue fell 57.71%, in the last year to $0.11 M. Its sector's average revenue growth for the last fiscal year was 8.01%.

Annual Net Profit$74.75 M45.31%positive

Annual Net Profit rose 45.31% in the last year to $74.75 M. Its sector's average net profit growth for the last fiscal year was 3.27%.

Price to Earning Ratio-1.59-negative

Price to Earning Ratio is -1.59, which is negative.

Stock Price$14.00384.43%positive

Stock Price rose 384.43% and outperformed its sector by 381.16% in the past year.

Quarterly Net profit$4.83 M30.45%positive

Quarterly Net profit rose 30.45% YoY to $4.83 M. Its sector's average net profit growth YoY for the quarter was 35.04%.

Debt to Equity Ratio1.32-negative

Debt to Equity Ratio of 1.32 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE)-126.06 %-126.06%negative

Return on Equity(ROE) for the last financial year was -126.06%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding0.73 %0%neutral

Mutual Fund Holding remained the same in the last quarter at 0.73%.

Institutional Holding2.85 %0%neutral

Institutional Holding remained the same in the last quarter at 2.85%.

VIEW LESS


Loading data..

Finch Therapeutics Group Inc - Company Profile

What does Finch Therapeutics Group Inc do?

Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).

Finch Therapeutics Group Inc Management structure

All Gross Remunerations are in USD
Mr. Lance Thibault, C.P.A.
Chief Financial Officer
-
2023
Gross Remuneration
Year
Dr. Mark Smith, PhD
Chief Executive Officer and Director
-
2023
Gross Remuneration
Year
Mr. Marc Blaustein
Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer
-
2023
Gross Remuneration
Year
Mr. Matthew P. Blischak
Chief Executive Officer
-
2023
Gross Remuneration
Year

Finch Therapeutics Group Inc Board of directors

All Gross Remunerations are in USD
Dr. Mark Smith, PhD
Chief Executive Officer and Director
-
2023
Gross Remuneration
Year
Mr. Nicholas Haft
Independent Director
-
2023
Gross Remuneration
Year

Finch Therapeutics Group Inc FAQ

How is Finch Therapeutics Group Inc today?
Finch Therapeutics Group Inc today is trading in the red, and is down by -0.71% at 14.00.
Finch Therapeutics Group Inc is currently trading down -0.71% on an intraday basis. In the past week the stock rose 2.19%. stock has been up 28.79% in the past quarter and rose 384.43% in the past year. You can view this in the overview section.